ADC Therapeutics Competitors and Similar CompaniesClear all
ADC Therapeutics's competitors and similar companies include Mersana Therapeutics, ImmunoGen, Immunomedics, Araris Biotech and Ajinomoto Bio-Pharma Services.
 ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers. |  Mersana Therapeutics Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. |  Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  Araris Biotech Araris Biotech is a biotechnology company with a new antibody-drug conjugate (ADC)-linker technology. |  Ajinomoto Bio-Pharma Services Ajinomoto Bio-Pharma Services (formerly known as Ajinomoto Althea) is a contract development and manufacturing organization (CDMO). | |
Founding Date | Founding Date 2010 | Founding Date 2005 | Founding Date 1981 | Founding Date 1982 | Founding Date 2019 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Private | Type Subsidiary |
Tags | ||||||
Locations | Locations Epalinges, CH HQ London, GB New Providence, US | Locations Cambridge, US HQ | Locations Waltham, US HQ | Locations Morris Plains, US HQ | Locations Zürich, CH HQ | Locations San Diego, US HQ Wetteren, BE Visakhapatnam, IN Osaka, JP |
Employees | Employees 1162% increase | Employees 11033% increase | Employees 277161% increase | Employees 8914% decrease | Employees 4 | Employees 68610% decrease |
Valuation ($) | Valuation ($) 295.9 m | Valuation ($) 250.3 m | Valuation ($) 8.7 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A |
Financial | ||||||
Revenue (est.) | Revenue (est.) $81.4m (FY, 2025) | Revenue (est.) $40.5m (FY, 2024) | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $5.1m (FY, 2025) | Cost of goods N/A | Cost of goods $176k (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $76.3m (FY, 2025) | Gross profit N/A | Gross profit $108.6m (FY, 2022) | Gross profit $295k (FY, 2019) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($142.6m) (FY, 2025) | Net income ($69.2m) (FY, 2024) | Net income ($222.9m) (FY, 2022) | Net income ($357.3m) (FY, 2019) | Net income N/A | Net income N/A |
Operating ⚠ | ||||||
Patents (US) | Patents (US) N/A | Patents (US) 7 (Apr, 2017) | Patents (US) N/A | Patents (US) 405 (Sep, 2022) | Patents (US) N/A | Patents (US) N/A |
Funding | ||||||
Total funding raised | Total funding raised $ 526m | Total funding raised $ 219.5m | Total funding raised $ 56m | Total funding raised $ 30m | Total funding raised $ 43.4m | Total funding raised $ 3.5m |
For sources of this data, please see the company profile
View Company Profiles
Mersana Therapeutics
HQ
Cambridge, US
Employees
110↑ 33% increase
Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms.
View companyImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View companyImmunomedics
HQ
Morris Plains, US
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companyAraris Biotech
HQ
Zürich, CH
Employees
4
Araris Biotech is a biotechnology company with a new antibody-drug conjugate (ADC)-linker technology.
View company